EUCTR2011-002908-33-IT进行中（未招募）不适用
A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non-Hodgkin’s lymphoma.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients, at least 18 years of age at Screening. 2.Untreated, histologically confirmed, stage III or IV NHL (CD20+Follicular Lymphoma of Grade 1, 2 or 3a, requiring chemiotherapy) 3. Patients not previously treated. Eligible patients previously on watch and wait (i.e. those patients who do not require treatment upfront at the time of the diagnosis)can enter the trial 4. ECOG performance status of 0 to 2. 5. Have a t least one measurable lesion as per the IWG criteria 2007 at Screening 6. Adequate hematological functions (unless abnormalities are related to lymphoma infiltration of the bone marrow) within 28 days prior to randomization, including: • Hemoglobin = 8,0 g/dL (= 5,0 mmol/L). • Absolute neutrophl count= 1,5 x 109/L. • Platelet count= 100 x 109/L. 7. Adequate renal and liver function. 8. For participants of reproductive potential (males and females), use of a medically acceptable method of contraception during the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 280
排除标准
- •1. Transformation to high-grade lymphoma (secondary to low grade lymphoma). 2. Presence or history of central nervous system (CNS) disease (either CNS lymphoma or lymphomatous meningitis). 3. Patients regularly taking oral corticosteroids must not be receiving a dose exceeding 20 mg/day prednisolone or equivalent. 4. Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, idarubicin and /or other anthracyclines and anthracenediones. 5. Patients with prior or concomitant magignancies 6. Major surgery (excluding lymph node biopsy) within 28 days prior to randomization. 7. Poor renal function: serum creatinine > 2.0 mg/dL (> 197 mcmol/L). 8. Poor hepatic function: total bilirubin > 2.0 mg/dL (> 34 mcmol/L) or aspartate aminotransferase (AST) > 3 times the upper limit of normal, unless these abnormalities are related to lymphoma. 9. Active, chronic or persistent infection that might worsen with immunosuppressive treatment 10. Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial 11. Patients with uncontrolled hypertension. 12. Known sensitivity or allergy to murine products. 13. History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug. 14. Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit. 15. Treatment within a clinical trial within 4 weeks prior to trial entry. 16. Pregnancy or breast feeding. For women of childbearing potential, a positive serum pregnancy test at the Screening Visit.
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy study in patients with untreated follicular non-Hodgkin´s lymphoma.EUCTR2011-002908-33-GBBoehringer Ingelheim International GmbH199,998
进行中（未招募）
不适用
Safety and efficacy study in patients with untreated follicular non-Hodgkin´s lymphoma.ntreated stage III or IV non-Hodgkin’s lymphoma (CD20+ Follicular Lymphoma of Grade 1, 2 or 3a, requiring chemotherapy)MedDRA version: 14.1Level: HLTClassification code 10016903Term: Follicle centre lymphomas, follicular grade I, II, IIISystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2011-002908-33-BEBoehringer Ingelheim International GmbH530
进行中（未招募）
不适用
Safety and efficacy study in patients with untreated follicular non-Hodgkin´s lymphoma.EUCTR2011-002908-33-CZBoehringer Ingelheim International GmbH530
进行中（未招募）
不适用
Safety and efficacy study in patients with untreated follicular non-Hodgkin´s lymphoma.ntreated stage III or IV non-Hodgkin’s lymphoma (CD20+ Follicular Lymphoma of Grade 1, 2 or 3a, requiring chemotherapy)MedDRA version: 18.1Level: HLTClassification code 10016903Term: Follicle centre lymphomas, follicular grade I, II, IIISystem Organ Class: 100000004851EUCTR2011-002908-33-SKBoehringer Ingelheim International GmbH530
进行中（未招募）
1 期
A Study Comparing SAIT101 to MabThera® in Patients with Low Tumor Burden Follicular Lymphomaow Tumor Burden Follicular Lymphoma (LTBFL)MedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2016-001966-27-HRArchigen Biotech Limited308